|
Match
|
Document |
Document Title |
|
|
7378234 |
Method for isolating hepatitis C virus peptides
Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule...
|
|
|
7344723 |
Self-replicating RNA molecule from hepatitis C virus
A unique HCV RNA molecule is provided having an enhanced efficiency of establishing cell culture replication. Novel adaptive mutations have been identified within the HCV non-structural region that...
|
|
|
7341726 |
Modified HCV peptide immunogens
Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated...
|
|
|
7329408 |
Eliciting HCV-specific antibodies
Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2...
|
|
|
7319144 |
Polynucleotides encoding a multiple epitope fusion antigen for use in an HCV antigen/antibody combination assay
The invention relates to a method of detecting HCV infection in a biological sample, the method comprising providing an immunoassay solid support, comprising an HCV anti-core antibody, an antigen...
|
|
|
7285539 |
Activation of HCV-specific T cells
The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4 + and CD8 + T cells. HCV-specific T cells are activated using fusion proteins comprising HCV...
|
|
|
7270820 |
CD4+ T-lymphocyte-specific hepatitis C virus epitopes
The invention relates to hepatitis C virus epitopes which are CD4 + T-lymphocyte specific, and to vaccines containing these epitopes.
|
|
|
7264811 |
Purified active HCV NS2/3 protease
A method for producing a refolded, inactive form of recombinantly produced NS2/3 protease which comprises the steps of: a) purifying the protease from inclusion bodies in the presence of a...
|
|
|
7255864 |
Diagnostic reagent for hepatitis C virus infection
A diagnostic reagent for hepatitis C virus infection obtained by sensitizing a solid phase with HCV antigen and a conjugated antigen prepared by chemical bonding of HCV antigen and a carrier...
|
|
|
7250166 |
Human monoclonal antibodies that bind hepatitis C virus (HCV) E1
The present invention relates to materials and methods for treatment of hepatitis C. More closely, the invention relates to human monoclonal antibodies against HCV E1 antigen, to a reagent...
|
|
|
7244585 |
3′ Sequence of the GB virus B (GBV-B) genome
The present invention relates generally to the fields of biochemistry, molecular biology, and virology. More particularly, it relates to the identification of 259 nucleotides located at the 3′...
|
|
|
7241440 |
Vaccines containing ribavirin and methods of use thereof
Compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans are disclosed. More particularly, vaccine compositions comprising...
|
|
|
7238356 |
Core-glycosylated HCV envelope proteins
The current invention relates to HCV envelope proteins or parts thereof which are the product of expression in eukaryotic cells. More particularly said HCV envelope proteins are characterized in...
|
|
|
7220420 |
Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
The present invention is directed to a molecule comprising a polypeptide having substantial homology with a CTL epitope selected from the group consisting of ADLMGYIPLV (Core 131-140 ; SEQ ID...
|
|
|
7201904 |
Epitopes of hepatitis C virus
The invention provides compositions containing HCV epitopes, which are recognized by cytotoxic T lymphocytes. Such polypeptides are used in prophylactic vaccines, immunotherapies, and assays to...
|
|
|
7183107 |
Enhanced replication of HCV RNA
This invention provides methods of generating cells that stably replicate sub-genomic virus replicons. This invention also provides methods of generating cells that have disabled PKR activity and...
|
|
|
7166426 |
HCV assay
An HCV antigen/antibody/antigen assay is provided. The assay employs an isolated first antigen from a region of the HCV polyprotein, and an HCV multiple epitope fusion antigen that includes an...
|
|
|
7166287 |
Viral agent
The invention relates to post-transfusional non-A non-B hepatitis viral polypeptide, DNA sequences encoding such viral polypeptide, expression vectors containing such DNA sequences, and hosts...
|
|
|
7138376 |
Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
A compound, method and composition for treating a host infected with a hepatitis C viral comprising administering an effective hepatitis C treatment amount of a described 4′-disubstituted...
|
|
|
7135185 |
Conserved motif of hepatitis C virus E2/NS1 region
Immunogenic compositions comprising an immunogenic polypeptide and a pharmaceutically acceptable vehicle are described. The immunogenic polypeptide comprises the amino acid sequence...
|
|
|
7108856 |
CD4+ T-lymphocyte-specific Hepatitis C virus-epitopes
The invention relates to Hepatitis C virus epitopes which are specific in relation to CD4+ T lymphocytes, in addition to vaccinations which contain said epitopes.
|
|
|
7108855 |
Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2,...
|
|
|
7101561 |
Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E2 and/or E1/E2,...
|
|
|
7101551 |
Remedies for hepatitis C
The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The...
|
|
|
7098303 |
Conserved motif of hepatitis C virus E2/NS1 region
Immunogenic polypeptides comprising hepatitis C virus (HCV) immunogens are described. The HCV immunogen comprises the amino acid sequence...
|
|
|
7094406 |
Enterically transmitted non-A/non-B hepatitis viral agent and characteristic epitopes thereof
Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in...
|
|
|
7084266 |
Cloned genome of infectious hepatitus C virus of genotype 2A and uses thereof
The present invention discloses nucleic acid sequence which encodes infectious hepatitis C virus of strain HC-J6 CH , gentotype 2a, and the use of the sequence, and polypeptides encoded by all or...
|
|
|
7074410 |
Modified HCV peptide vaccines
Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated...
|
|
|
7070790 |
Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
The nucleotide and deduced amino acid sequences of cDNAs encoding the envelope 1 genes and core genes of isolates of hepatitis C virus (HCV) are disclosed. The invention relates to the...
|
|
|
7056658 |
Multiple epitope fusion protein
Multiple epitope fusion proteins and immunoassays using the same are disclosed. The multiple epitope fusion proteins are encompassed by the general structural formula (A) x −(B) y −C 2 which...
|
|
|
7052696 |
Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
Antigenic epitopes of hepatitis C virus (HCV) and mosaic HCV polypeptides useful as reagents in assays for the diagnosis or monitoring of HCV in a biological sample. The antigenic epitopes and...
|
|
|
7048930 |
Expression of core-glycosylated HCV envelope proteins in yeast
The present invention relates to the general field of recombinant protein expression, purification of recombinant proteins, diagnosis of HCV infection, prophylactic treatment against HCV infection...
|
|
|
7034108 |
Mimotopes of hypervariable region 1 of the E2 glycoprotein of HCV and uses thereof
Peptides which are mimotopes of the hypervariable region 1 (HVR1) of the putative envelope protein E2 of hepatitis C virus (HCV) are provided, useful in obtaining antibodies and raising an immune...
|
|
|
6986892 |
Immunogenic Hepatitis C virus non-structural polypeptides
Polypeptides comprising a mutant non-structural Hepatitis C virus useful in diagnostic and/or immunogenic compositions are disclosed, in which the mutant is an N-terminal mutation that functionally...
|
|
|
6974864 |
Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes...
|
|
|
6964852 |
Antigenic structural peptide, antigenic and immunogenic compounds, and uses for detecting, preventing and treating an HCV infection
The invention concerns a structural peptide, identified by antibodies directed against a polypeptide, comprising the 2-45 amino acid sequence of the N-terminal end of the Core or nucleocapsid (p21)...
|
|
|
6960659 |
Mosaic protein and restriction endonuclease assisted ligation method for making the same
A mosaic protein comprising a variety of immunoreactive antigenic epitopes from several genotypes of hepatitis C virus. The mosaic protein provides a sensitive and specific immunological hepatitis...
|
|
|
6946448 |
In utero oral nucleic acid immunization
Methods of nucleic acid immunization comprising the in utero delivery of nucleic acid molecules that encode one or more selected antigens to a vertebrate fetus are disclosed.
|
|
|
6943246 |
3′terminal sequence of hepatitis C virus genome and diagnostic and therapeutic uses thereof
The invention relates to the discovery of a novel RNA sequence at the 3′ terminal sequence of hepatitis C virus (HCV) genome RNA. Included in the invention are the 3′ sequence, its complement,...
|
|
|
6887484 |
Vaccine composition containing a promoter peptide
A vaccine having a good vaccination effect, which comprises an antigen; a peptide selected from the group consisting of a peptide having the amino acid sequence of SEQ ID NO: 1, a peptide having...
|
|
|
6855318 |
Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes
Multimer peptides (e.g. 30- to 45-mer peptides) derived from hepatitis C virus envelope proteins reacting with the majority of anti-HCV antibodies present in patient sera are described. The usage...
|
|
|
6849429 |
Viral pseudo-capsids including assembly agonists and antagonists
Recombinant hepatitis C virus (HCV) capsid proteins that self-assemble into large spherical virus-like particles structures and viral capsids that include conformational antigenic epitopes are...
|
|
|
6841353 |
Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
Antibodies to two new epitopes on the HCV envelope proteins were identified which allow routine detection of native HCV envelope antigens, in tissue or cells derived from the host. The new epitopes...
|
|
|
6828139 |
Production of replicative hepatitis C virus
A nucleic acid having a first nucleotide sequence encoding an infectious hepatitis C virus, a second nucleotide sequence encoding a ribozyme, and an inducible promoter operably linked to the first...
|
|
|
6824768 |
Ribavirin-pegylated interferon alfa induction HCV combination therapy
There is disclosed a method for treating antiviral treatment naives patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using (1) a...
|
|
|
6797809 |
Multiple fusion antigens for use in immunoassays for anti-HCV antibodies
HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.
|
|
|
6787145 |
Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the...
|
|
|
6692751 |
Methods and systems for producing recombinant viral antigens
The present invention relates to recombinant expression vectors which express segments of deoxyribonucleic acid that encode recombinant HIV and HCV antigens. These recombinant expression vectors...
|
|
|
6689368 |
Immunodominant human T-cell epitopes of hepatitis C virus
The present invention relates to a polypeptide of about 8 to about 100 amino acids comprising or consisting of at least 8 contiguous amino acids selected from the core, and/or the NS3 regions of...
|
|
|
6680059 |
Vaccines containing ribavirin and methods of use thereof
The present invention relates to compositions and methods for enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans. More particularly, the use of...
|